AgomAb Therapeutics, a Belgian Phase 2 biotech developing novel therapies for chronic fibrotic disorders, raised $200 million by offering 12.5 million ADSs at $16, the midpoint of the range of $15 to $17. AgomAb Therapeutics is a clinical-stage...read more
Updated Monday, 2/2. Eight IPOs raising at least $100 million are currently scheduled for the week ahead. If all eight deals price, it would be the busiest week for sizable offerings since 2021. Only one other week over the past four years has produced seven...read more
AgomAb Therapeutics, a Belgian Phase 2 biotech developing TGFβ inhibitors for Crohn's and other fibrotic diseases, announced terms for its IPO on Thursday. The Antwerp, Belgium-based company plans to raise $200 million by offering 12.5 million shares at a ...read more
AgomAb Therapeutics, a Belgium-based Phase 2 biotech focused on immunology and inflammatory diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering. AgomAb Therapeutics is a clinical-stage biopharmaceutical company...read more
Belgian fibrotic disease biotech AgomAb Therapeutics prices IPO at $16 midpoint, raising $200 million
AgomAb Therapeutics, a Belgian Phase 2 biotech developing novel therapies for chronic fibrotic disorders, raised $200 million by offering 12.5 million ADSs at $16, the midpoint of the range of $15 to $17. AgomAb Therapeutics is a clinical-stage...read more
US IPO Week Ahead: At least 8 sizable IPOs teed up in one of the busiest weeks in four years
Updated Monday, 2/2. Eight IPOs raising at least $100 million are currently scheduled for the week ahead. If all eight deals price, it would be the busiest week for sizable offerings since 2021. Only one other week over the past four years has produced seven...read more
Belgian fibrotic disease biotech AgomAb Therapeutics sets terms for $200 million US IPO
AgomAb Therapeutics, a Belgian Phase 2 biotech developing TGFβ inhibitors for Crohn's and other fibrotic diseases, announced terms for its IPO on Thursday. The Antwerp, Belgium-based company plans to raise $200 million by offering 12.5 million shares at a ...read more
Belgian immunology and inflammatory biotech AgomAb Therapeutics files for a $100 million US IPO
AgomAb Therapeutics, a Belgium-based Phase 2 biotech focused on immunology and inflammatory diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering. AgomAb Therapeutics is a clinical-stage biopharmaceutical company...read more